BioAZ

BioAZ is a biotech company that develops biodegradable immunotherapies for animal health and welfare.   

You can learn more about our company and our flagship project in this 3-minute video: https://youtu.be/Hx8ABG-YDGQ 

Our first innovation is a biodegradable alternative to pig castration, a major step forward for animal welfare. This product, painless for the animal, allows farmers to win 15 minutes and 5 to 6 euros per pig and addresses a worldwide market over €3 billion. Two other innovations are being developed: an alternative to castration for companion animals and an alternative to antibiotics for calves. 

In addition, BioAZ is the winner of the Pignnovation Award organized by MSD Animal Health, the 2nd largest global player in animal health with a turnover of USD 5.6 billion in 2023 (1st in Swine). This distinction is translated in an endowment of 75,000 USD for BioAZ with a right of first refusal for MSD. 

Founded in 2022 by Romain Delcombel, a veterinarian and expert in the development of biotechnologies for animal health, BioAZ relies on the expertise of veterinary and scientific shareholders, including the group Cristal (the leading network of French rural veterinarians), as well as an internationally recognized advisory committee. We are actively working on the industrialization of our solution and are preparing the first clinical trials in pigs. 

Our objectives: to finalize the first phase of development, including the industrialization stages and clinical trials of our patented technology, adapted to dogs and pigs, before licensing to a major veterinary pharmaceutical company. To do this, we are raising €2 million (465k already secured from historical investors) to: 

• Finalize the final stages of R&D and extend our patent before granting a first license for the alternative to pig castration. 
• Accelerating the development of our two other projects

KPI summary:

• 3 R&D projects 
• 2 laboratory PoC done
• 2 animal PoC done
• 1 patent applied at EUIPO and extended in PCT procedure
• 1 right of first refusal with MSD Animal health (N°2 vet big pharma) and ongoing discussions with 6 competitors (4 LOI signed: Ceva, Virbac, Huvepharma and Hipra)